LCTX
Lineage Cell Therapeutics, Inc.
Price Chart
Latest Quote
$1.21
-0.05 (-3.97%)
Current Price
| Previous Close | $1.26 |
| Open | $1.26 |
| Day High | $1.28 |
| Day Low | $1.20 |
| Volume | 715,392 |
Stock Information
| Shares Outstanding | 249.30M |
| Total Debt | $2.39M |
| Cash Equivalents | $53.38M |
| Revenue | $14.78M |
| Net Income | $-64.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $301.65M |
| EPS (TTM) | $-0.29 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $259.46M |
| Sales | $14.78M |
| Income | $-64.21M |
| Book/sh | $0.22 |
| Cash/sh | $0.21 |
| Employees | 72 |
Financial Ratios
| Quick Ratio | 6.72 |
| Current Ratio | 6.89 |
| Debt/Eq | 4.54 |
Returns & Margins
| ROA | -12.92% |
| ROE | -98.22% |
| Gross Margin | -28.28% |
| Operating Margin | -440.17% |
Ownership
| Insider Ownership | 4.93% |
| Institutional Ownership | 47.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.44 |
| PEG | 10.64 |
| P/S | 20.41 |
| P/B | 5.60 |
Analyst Data
| Recommendation | none |
| Target Price | $5.50 |
Technical Indicators
| SMA20 | $1.24 |
| SMA50 | $1.36 |
| SMA200 | $1.60 |
| RSI | 50.00 |
| ATR | 0.0648 |
| Shares Float | 187.28M |
| Short Float | 17.52% |
| Short Ratio | 18.80 |
| Volatility | 1.51 |
| Rel Volume | 0.64 |
Performance History
| Week | -3.20% |
| Month | -6.20% |
| Quarter | -21.94% |
| 6 Months | -30.06% |
| YTD | -26.22% |
| Year | +12.04% |
| 3 Years | -18.24% |
| 5 Years | -57.39% |
| 10 Years | -39.61% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.21 | 715,392 |
| 2026-06-24 | $1.26 | 778,100 |
| 2026-06-23 | $1.25 | 727,900 |
| 2026-06-22 | $1.26 | 1,514,900 |
| 2026-06-18 | $1.21 | 1,697,900 |
| 2026-06-17 | $1.25 | 1,392,300 |
| 2026-06-16 | $1.20 | 1,649,600 |
| 2026-06-15 | $1.23 | 1,318,700 |
| 2026-06-12 | $1.27 | 1,018,600 |
| 2026-06-11 | $1.28 | 908,700 |
| 2026-06-10 | $1.23 | 1,316,800 |
| 2026-06-09 | $1.22 | 1,396,000 |
| 2026-06-08 | $1.21 | 1,098,300 |
| 2026-06-05 | $1.19 | 980,600 |
| 2026-06-04 | $1.21 | 692,100 |
| 2026-06-03 | $1.20 | 807,800 |
| 2026-06-02 | $1.21 | 1,697,000 |
| 2026-06-01 | $1.26 | 972,200 |
| 2026-05-29 | $1.33 | 639,100 |
| 2026-05-28 | $1.33 | 926,600 |
| 2026-05-27 | $1.30 | 674,600 |
| 2026-05-26 | $1.29 | 1,232,700 |
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
đ° Latest News
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage
Simply Wall St. âĸ 2026-06-18T16:20:49Z
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets
Simply Wall St. âĸ 2026-06-04T13:12:01Z
Promising Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-26T12:05:34Z
Lineage Cell Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-15T23:10:49Z
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-05-13T05:02:26ZLineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T21:10:01Z
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-11T21:15:02Z
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T21:55:05Z
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration
Simply Wall St. âĸ 2026-04-15T18:05:23Z
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program
Insider Monkey âĸ 2026-03-31T07:19:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $146,000 | $334,000 | $671,000 | $728,000 |
| Cost Of Revenue | $146,000 | $334,000 | $671,000 | $728,000 |
| Total Revenue | $14,556,000 | $9,499,000 | $8,945,000 | $14,703,000 |
| Operating Revenue | $14,556,000 | $9,499,000 | $8,945,000 | $14,703,000 |
| Expenses | ||||
| Total Expenses | $36,335,000 | $30,977,000 | $33,678,000 | $37,223,000 |
| Other Income Expense | $-48,567,000 | $1,173,000 | $-178,000 | $-4,121,000 |
| Other Non Operating Income Expenses | $-132,000 | $-670,000 | $542,000 | $-2,152,000 |
| Net Non Operating Interest Income Expense | $1,691,000 | $1,715,000 | $1,629,000 | $829,000 |
| Operating Expense | $36,189,000 | $30,643,000 | $33,007,000 | $36,495,000 |
| General And Administrative Expense | $18,460,000 | $18,171,000 | $17,302,000 | $22,508,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-63,533,000 | $-18,609,000 | $-21,486,000 | $-26,273,000 |
| Net Interest Income | $1,691,000 | $1,715,000 | $1,629,000 | $829,000 |
| Interest Income | $1,691,000 | $1,715,000 | $1,629,000 | $829,000 |
| Normalized Income | $-18,846,869 | $-20,452,000 | $-20,823,600 | $-24,717,490 |
| Net Income From Continuing And Discontinued Operation | $-63,533,000 | $-18,609,000 | $-21,486,000 | $-26,273,000 |
| Total Operating Income As Reported | $-36,619,000 | $-21,478,000 | $-24,733,000 | $-22,520,000 |
| Net Income Common Stockholders | $-63,533,000 | $-18,609,000 | $-21,486,000 | $-26,273,000 |
| Net Income | $-63,533,000 | $-18,609,000 | $-21,486,000 | $-26,273,000 |
| Net Income Including Noncontrolling Interests | $-63,367,000 | $-18,582,000 | $-21,479,000 | $-26,353,000 |
| Net Income Continuous Operations | $-63,367,000 | $-18,582,000 | $-21,479,000 | $-26,353,000 |
| Pretax Income | $-68,647,000 | $-18,582,000 | $-23,282,000 | $-25,812,000 |
| Special Income Charges | $-14,840,000 | $0 | - | $0 |
| Interest Income Non Operating | $1,691,000 | $1,715,000 | $1,629,000 | $829,000 |
| Operating Income | $-21,779,000 | $-21,478,000 | $-24,733,000 | $-22,520,000 |
| Gross Profit | $14,410,000 | $9,165,000 | $8,274,000 | $13,975,000 |
| Per Share | ||||
| Diluted EPS | $-0.28 | $-0.09 | $-0.12 | $-0.15 |
| Basic EPS | $-0.28 | $-0.09 | $-0.12 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,748,869 | $0 | $-57,600 | $-413,490 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $27,355,000 | $-22,712,000 | $-23,321,000 | $-19,824,000 |
| Total Unusual Items | $-48,435,000 | $1,843,000 | $-720,000 | $-1,969,000 |
| Total Unusual Items Excluding Goodwill | $-48,435,000 | $1,843,000 | $-720,000 | $-1,969,000 |
| Reconciled Depreciation | $699,000 | $609,000 | $692,000 | $727,000 |
| EBITDA (Bullshit earnings) | $-21,080,000 | $-20,869,000 | $-24,041,000 | $-21,793,000 |
| EBIT | $-21,779,000 | $-21,478,000 | $-24,733,000 | $-22,520,000 |
| Diluted Average Shares | $230,116,000 | $200,193,000 | $172,663,000 | $169,792,000 |
| Basic Average Shares | $230,116,000 | $200,193,000 | $172,663,000 | $169,792,000 |
| Diluted NI Availto Com Stockholders | $-63,533,000 | $-18,609,000 | $-21,486,000 | $-26,273,000 |
| Minority Interests | $-166,000 | $-27,000 | $-7,000 | $80,000 |
| Tax Provision | $-5,280,000 | $0 | $-1,803,000 | $541,000 |
| Impairment Of Capital Assets | $14,840,000 | $0 | - | - |
| Gain On Sale Of Security | $-33,595,000 | $1,843,000 | $-720,000 | $-1,969,000 |
| Research And Development | $17,729,000 | $12,472,000 | $15,705,000 | $13,987,000 |
| Selling General And Administration | $18,460,000 | $18,171,000 | $17,302,000 | $22,508,000 |
| Other Gand A | $18,460,000 | $18,171,000 | $17,302,000 | $22,508,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,177,000 | $21,169,000 | $6,185,000 | $15,975,000 |
| Total Assets | $112,584,000 | $113,218,000 | $101,019,000 | $123,664,000 |
| Total Non Current Assets | $53,427,000 | $62,221,000 | $62,578,000 | $63,664,000 |
| Other Non Current Assets | $558,000 | $614,000 | $577,000 | $627,000 |
| Non Current Deferred Assets | $5,800,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $5,800,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $42,372,000 | $57,212,000 | $57,234,000 | $57,364,000 |
| Other Intangible Assets | $31,700,000 | $46,540,000 | $46,562,000 | $46,692,000 |
| Current Assets | $59,157,000 | $50,997,000 | $38,441,000 | $60,000,000 |
| Other Current Assets | $2,485,000 | $2,554,000 | $2,204,000 | $1,828,000 |
| Receivables | $891,000 | $638,000 | $745,000 | $297,000 |
| Accounts Receivable | $891,000 | $638,000 | $745,000 | $297,000 |
| Cash Cash Equivalents And Short Term Investments | $55,781,000 | $47,805,000 | $35,492,000 | $57,875,000 |
| Cash And Cash Equivalents | $40,791,000 | $45,789,000 | $35,442,000 | $11,355,000 |
| Allowance For Doubtful Accounts Receivable | - | $0 | $-100,000 | $-100,000 |
| Gross Accounts Receivable | - | $638,000 | $845,000 | $397,000 |
| Non Current Prepaid Assets | - | - | - | $627,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $2,419,000 | $2,514,000 | $2,952,000 | $3,896,000 |
| Long Term Debt And Capital Lease Obligation | $1,566,000 | $1,362,000 | $2,070,000 | $2,944,000 |
| Current Debt And Capital Lease Obligation | $853,000 | $1,152,000 | $882,000 | $952,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $69,238,000 | $36,206,000 | $38,996,000 | $51,728,000 |
| Total Non Current Liabilities Net Minority Interest | $57,871,000 | $22,229,000 | $21,036,000 | $32,747,000 |
| Derivative Product Liabilities | $43,906,000 | $6,161,000 | $0 | - |
| Non Current Deferred Liabilities | $12,399,000 | $14,706,000 | $18,966,000 | $29,801,000 |
| Non Current Deferred Taxes Liabilities | $22,000 | $273,000 | $273,000 | $2,076,000 |
| Current Liabilities | $11,367,000 | $13,977,000 | $17,960,000 | $18,981,000 |
| Current Deferred Liabilities | $3,333,000 | $7,388,000 | $10,808,000 | $9,421,000 |
| Payables And Accrued Expenses | $3,437,000 | $2,371,000 | $3,147,000 | $6,226,000 |
| Payables | $2,341,000 | $1,174,000 | $2,050,000 | $2,393,000 |
| Accounts Payable | $2,341,000 | $1,174,000 | $2,050,000 | $2,393,000 |
| Other Non Current Liabilities | - | - | - | $2,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $44,549,000 | $78,381,000 | $63,419,000 | $73,339,000 |
| Total Equity Gross Minority Interest | $43,346,000 | $77,012,000 | $62,023,000 | $71,936,000 |
| Stockholders Equity | $44,549,000 | $78,381,000 | $63,419,000 | $73,339,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,920,000 | $-2,876,000 | $-3,068,000 | $-3,571,000 |
| Other Equity Adjustments | $-3,920,000 | $-2,876,000 | $-3,068,000 | $-3,571,000 |
| Retained Earnings | $-466,998,000 | $-403,465,000 | $-384,856,000 | $-363,370,000 |
| Other | ||||
| Ordinary Shares Number | $243,121,801 | $220,416,326 | $174,986,671 | $170,093,000 |
| Share Issued | $243,121,801 | $220,416,326 | $174,986,671 | $170,093,000 |
| Tangible Book Value | $2,177,000 | $21,169,000 | $6,185,000 | $15,975,000 |
| Invested Capital | $44,549,000 | $78,381,000 | $63,419,000 | $73,339,000 |
| Working Capital | $47,790,000 | $37,020,000 | $20,481,000 | $41,019,000 |
| Capital Lease Obligations | $2,419,000 | $2,514,000 | $2,952,000 | $3,896,000 |
| Total Capitalization | $44,549,000 | $78,381,000 | $63,419,000 | $73,339,000 |
| Minority Interest | $-1,203,000 | $-1,369,000 | $-1,396,000 | $-1,403,000 |
| Capital Stock | $515,467,000 | $484,722,000 | $451,343,000 | $440,280,000 |
| Common Stock | $515,467,000 | $484,722,000 | $451,343,000 | $440,280,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $12,377,000 | $14,433,000 | $18,693,000 | $27,725,000 |
| Long Term Capital Lease Obligation | $1,566,000 | $1,362,000 | $2,070,000 | $2,944,000 |
| Current Deferred Revenue | $3,333,000 | $7,388,000 | $10,808,000 | $9,421,000 |
| Current Capital Lease Obligation | $853,000 | $1,152,000 | $882,000 | $952,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,744,000 | $3,066,000 | $3,123,000 | $2,382,000 |
| Current Accrued Expenses | $1,096,000 | $1,197,000 | $1,097,000 | $3,833,000 |
| Goodwill | $10,672,000 | $10,672,000 | $10,672,000 | $10,672,000 |
| Net PPE | $4,697,000 | $4,395,000 | $4,767,000 | $5,673,000 |
| Accumulated Depreciation | $-5,684,000 | $-4,384,000 | $-3,880,000 | $-5,850,000 |
| Gross PPE | $10,381,000 | $8,779,000 | $8,647,000 | $11,523,000 |
| Leases | $2,749,000 | $2,300,000 | $2,313,000 | $2,150,000 |
| Other Properties | $2,352,000 | $2,348,000 | $2,720,000 | $6,109,000 |
| Machinery Furniture Equipment | $5,280,000 | $4,131,000 | $3,614,000 | $3,264,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $14,990,000 | $2,016,000 | $50,000 | $46,520,000 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,441,000 | $-23,657,000 | $-29,240,000 | $646,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,919,000 | $-23,092,000 | $-28,566,000 | $1,059,000 |
| Cash Flow From Continuing Operating Activities | $-18,919,000 | $-23,092,000 | $-28,566,000 | $1,059,000 |
| Operating Gains Losses | $33,466,000 | $-1,847,000 | $776,000 | $4,230,000 |
| Investing Activities | ||||
| Capital Expenditure | $-522,000 | $-565,000 | $-674,000 | $-413,000 |
| Investing Cash Flow | $-13,457,000 | $-2,308,000 | $46,449,000 | $-46,159,000 |
| Cash Flow From Continuing Investing Activities | $-13,457,000 | $-2,308,000 | $46,449,000 | $-46,159,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-16,000 | $-23,000 | $-37,000 | $-17,000 |
| Issuance Of Capital Stock | $26,140,000 | $35,876,000 | $6,426,000 | $148,000 |
| Financing Cash Flow | $26,950,000 | $35,857,000 | $6,423,000 | $1,632,000 |
| Cash Flow From Continuing Financing Activities | $26,950,000 | $35,857,000 | $6,423,000 | $1,632,000 |
| Net Other Financing Charges | $-684,000 | $-171,000 | $-199,000 | $-106,000 |
| Net Common Stock Issuance | $26,124,000 | $35,853,000 | $6,389,000 | $131,000 |
| Common Stock Issuance | $26,140,000 | $35,876,000 | $6,426,000 | $148,000 |
| Other | ||||
| Repayment Of Debt | $-59,000 | $-54,000 | $-54,000 | $-32,000 |
| Interest Paid Supplemental Data | $29,000 | $9,000 | $10,000 | $13,000 |
| End Cash Position | $41,324,000 | $46,354,000 | $35,992,000 | $11,936,000 |
| Beginning Cash Position | $46,354,000 | $35,992,000 | $11,936,000 | $56,277,000 |
| Effect Of Exchange Rate Changes | $396,000 | $-95,000 | $-250,000 | $-873,000 |
| Changes In Cash | $-5,426,000 | $10,457,000 | $24,306,000 | $-43,468,000 |
| Proceeds From Stock Option Exercised | $1,569,000 | $229,000 | $88,000 | $1,639,000 |
| Common Stock Payments | $-16,000 | $-23,000 | $-37,000 | $-17,000 |
| Net Issuance Payments Of Debt | $-59,000 | $-54,000 | $-54,000 | $-32,000 |
| Net Long Term Debt Issuance | $-59,000 | $-54,000 | $-54,000 | $-32,000 |
| Long Term Debt Payments | $-59,000 | $-54,000 | $-54,000 | $-32,000 |
| Net Investment Purchase And Sale | $-12,935,000 | $-1,743,000 | $47,123,000 | $-45,746,000 |
| Sale Of Investment | $2,000,000 | $7,018,000 | $63,526,000 | $7,666,000 |
| Purchase Of Investment | $-14,935,000 | $-8,761,000 | $-16,403,000 | $-53,412,000 |
| Net PPE Purchase And Sale | $-522,000 | $-565,000 | $-674,000 | $-413,000 |
| Purchase Of PPE | $-522,000 | $-565,000 | $-674,000 | $-413,000 |
| Change In Working Capital | $-4,110,000 | $-8,766,000 | $-10,804,000 | $18,704,000 |
| Change In Other Working Capital | $-6,111,000 | $-7,680,000 | $-7,645,000 | $-13,354,000 |
| Change In Payables And Accrued Expense | $2,271,000 | $-1,681,000 | $-2,295,000 | $-18,702,000 |
| Change In Prepaid Assets | $46,000 | $489,000 | $-418,000 | $446,000 |
| Change In Receivables | $-316,000 | $106,000 | $-446,000 | $50,314,000 |
| Changes In Account Receivables | $-316,000 | $106,000 | $-446,000 | $50,314,000 |
| Other Non Cash Items | $81,000 | $417,000 | $-588,000 | $-536,000 |
| Stock Based Compensation | $4,752,000 | $5,077,000 | $4,640,000 | $4,287,000 |
| Asset Impairment Charge | $14,840,000 | $0 | - | - |
| Deferred Tax | $-5,280,000 | $0 | $-1,803,000 | $0 |
| Deferred Income Tax | $-5,280,000 | $0 | $-1,803,000 | $0 |
| Depreciation Amortization Depletion | $699,000 | $609,000 | $692,000 | $727,000 |
| Depreciation And Amortization | $699,000 | $609,000 | $692,000 | $727,000 |
| Amortization Cash Flow | $0 | $22,000 | $130,000 | $145,000 |
| Amortization Of Intangibles | $0 | $22,000 | $130,000 | $145,000 |
| Depreciation | $699,000 | $587,000 | $562,000 | $582,000 |
| Gain Loss On Investment Securities | $35,735,000 | $-2,120,000 | $176,000 | $1,969,000 |
| Net Foreign Currency Exchange Gain Loss | $-2,269,000 | $273,000 | $600,000 | $2,272,000 |
| Net Income From Continuing Operations | $-63,367,000 | $-18,582,000 | $-21,479,000 | $-26,353,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $2,194,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-25